Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA – Journal of the American Medical Association. 2020; 323: 548–60. DOI: https://doi.org/10.1001/jama.2019.22360 

Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Movement Disorders. 2014; 29: 454–62. DOI: https://doi.org/10.1002/mds.25844 

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience. 2017; 18: 435–50. DOI: https://doi.org/10.1038/nrn.2017.62 

Zach H, Dirkx M, Bloem BR, et al. The clinical evaluation of Parkinson’s tremor. Journal of Parkinson’s Disease. 2015; 5: 471–4. DOI: https://doi.org/10.3233/JPD-150650 

Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: The patient’s perspective. Movement Disorders. 2010; 25: 1646–51. DOI: https://doi.org/10.1002/mds.23135 

Kipfer S. Resting Tremor in Parkinson Disease. Archives of Neurology. 2011; 68: 1037. DOI: https://doi.org/10.1001/archneurol.2011.147 

Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson’s disease: A clinical and neuroimaging study. Brain. 2018; 141: 811–21. DOI: https://doi.org/10.1093/brain/awx376 

Gironell A, Pascual-Sedano B, Aracil I, et al. Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson’s Disease; 2018. DOI: https://doi.org/10.1155/2018/4327597 

van Rooden SM, Heiser WJ, Kok JN, et al. The identification of Parkinson’s disease subtypes using cluster analysis: A systematic review. Movement Disorders. 2010; 25: 969–78. DOI: https://doi.org/10.1002/mds.23116 

Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale. Movement Disorders. 2013; 28: 668–70. DOI: https://doi.org/10.1002/mds.25383 

Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013; 84(4): 409–415. DOI: https://doi.org/10.1136/jnnp-2012-303455 

Aleksovski D, Miljkovic D, Bravi D, et al. Disease progression in Parkinson subtypes: the PPMI dataset. Neurological Sciences. 2018; 39: 1971–6. DOI: https://doi.org/10.1007/s10072-018-3522-z 

Fishman PS. Paradoxical aspects of parkinsonian tremor. Movement Disorders. 2008; 23: 168–73. DOI: https://doi.org/10.1002/mds.21736 

Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA – Journal of the American Medical Association. 2014; 311: 1670–83. DOI: https://doi.org/10.1001/jama.2014.3654 

Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry. 2020; 91: 795–808. DOI: https://doi.org/10.1136/jnnp-2019-322338 

Rajput AH, Voll A, Rajput ML, et al. Course in parkinson disease subtypes: A 39-year clinicopathologic study. Neurology. 2009; 73: 206–12. DOI: https://doi.org/10.1212/WNL.0b013e3181ae7af1 

Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurology. 2014; 71: 499–504. DOI: https://doi.org/10.1001/jamaneurol.2013.6233 

Hallett M. Parkinson’s disease tremor: Pathophysiology. Parkinsonism and Related Disorders. 2012; 18: S85–6. DOI: https://doi.org/10.1016/S1353-8020(11)70027-X 

Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. Curr Opin Neurol. 2020; 33(4): 474–481. DOI: https://doi.org/10.1097/WCO.0000000000000829 

Hallett M. Tremor: pathophysiology. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S118–S122. DOI: https://doi.org/10.1016/S1353-8020(13)70029-4 

Helmich RC, Dirkx MF. Pathophysiology and Management of Parkinsonian Tremor. Seminars in Neurology. 2017; 37: 127–34. DOI: https://doi.org/10.1055/s-0037-1601558 

Helmich RC. The cerebral basis of Parkinsonian tremor: A network perspective. Movement Disorders. 2018; 33: 219–31. DOI: https://doi.org/10.1002/mds.27224 

Helmich RC, Hallett M, Deuschl G, et al. Cerebral causes and consequences of parkinsonian resting tremor: A tale of two circuits? Brain. 2012; 135: 3206–26. DOI: https://doi.org/10.1093/brain/aws023 

Dirkx MF, Bologna M. The pathophysiology of Parkinson’s disease tremor. Journal of the Neurological Sciences. 2022; 435: 120196. DOI: https://doi.org/10.1016/j.jns.2022.120196 

Timmermann L, Gross J, Dirks M, et al. The cerebral oscillatory network of parkinsonian resting tremor. Brain. 2003; 126: 199–212. DOI: https://doi.org/10.1093/brain/awg022 

Dirkx MF, den Ouden H, Aarts E, et al. The cerebral network of parkinson’s tremor: An effective connectivity fMRI study. Journal of Neuroscience. 2016; 36: 5362–72. DOI: https://doi.org/10.1523/JNEUROSCI.3634-15.2016 

Dirkx MF, den Ouden HEM, Aarts E, et al. Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus. Brain. 2017; 140: 721–34. DOI: https://doi.org/10.1093/brain/aww331 

Kremer NI, Pauwels RWJ, Pozzi NG, et al. Deep brain stimulation for tremor: Update on long-term outcomes, target considerations and future directions. Journal of Clinical Medicine. 2021; 10. DOI: https://doi.org/10.3390/jcm10163468 

Duval C, Daneault JF, Hutchison WD, et al. A brain network model explaining tremor in Parkinson’s disease. Neurobiology of Disease. 2016; 85: 49–59. DOI: https://doi.org/10.1016/j.nbd.2015.10.009 

Helmich RC, Janssen MJR, Oyen WJG, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Annals of Neurology. 2011; 69: 269–81. DOI: https://doi.org/10.1002/ana.22361 

Underwood CF, Parr-Brownlie LC. Primary motor cortex in Parkinson’s disease: Functional changes and opportunities for neurostimulation. Neurobiology of Disease. 2021; 147. DOI: https://doi.org/10.1016/j.nbd.2020.105159 

Burciu RG, Vaillancourt DE. Imaging of Motor Cortex Physiology in Parkinson’s Disease. Movement Disorders. 2018; 33: 1688–99. DOI: https://doi.org/10.1002/mds.102 

Ni Z, Pinto AD, Lang AE, et al. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Annals of Neurology. 2010; 68: 816–24. DOI: https://doi.org/10.1002/ana.22221 

Lu MK, Chiou SM, Ziemann U, et al. Resetting tremor by single and paired transcranial magnetic stimulation in Parkinson’s disease and essential tremor. Clinical Neurophysiology. 2015; 126: 2330–6. DOI: https://doi.org/10.1016/j.clinph.2015.02.010 

Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Movement Disorders. 2012; 27: 8–30. DOI: https://doi.org/10.1002/mds.23795 

Lee JY, Lao-Kaim NP, Pasquini J, et al. Pallidal dopaminergic denervation and rest tremor in early Parkinson’s disease: PPMI cohort analysis. Parkinsonism and Related Disorders. 2018; 51: 101–4. DOI: https://doi.org/10.1016/j.parkreldis.2018.02.039 

Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol. 1991; 50(6): 743–755. DOI: https://doi.org/10.1097/00005072-199111000-00006 

den Dunnen WF. Neuropathological diagnostic considerations in hyperkinetic movement disorders. Front Neurol. 2013; 4: 7. Published 2013 Feb 14. DOI: https://doi.org/10.3389/fneur.2013.00007 

Isaias IU, Marotta G, Pezzoli G, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology. 2011; 11. DOI: https://doi.org/10.1186/1471-2377-11-88 

Zach H, Dirkx MF, Pasman JW, et al. Cognitive Stress Reduces the Effect of Levodopa on Parkinson’s Resting Tremor. CNS Neuroscience and Therapeutics. 2017; 23: 209–15. DOI: https://doi.org/10.1111/cns.12670 

Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015; 138: 2964–73. DOI: https://doi.org/10.1093/brain/awv215 

Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: An [123I] β-CIT SPECT study. Journal of Neural Transmission. 2008; 115: 721–9. DOI: https://doi.org/10.1007/s00702-007-0015-2 

Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. Npj Parkinson’s Disease. 2016; 2. DOI: https://doi.org/10.1038/npjparkd.2016.1 

Lenka A, Jankovic J. Tremor Syndromes: An Updated Review. Frontiers in Neurology. 2021; 12: 1–17. DOI: https://doi.org/10.3389/fneur.2021.684835 

Hess CW, Pullman SL. Tremor: Clinical phenomenology and assessment techniques. Tremor and Other Hyperkinetic Movements. 2012; 2: 1–15. DOI: https://doi.org/10.5334/tohm.115 

Dirkx MF, Zach H, Bloem BR, et al. The nature of postural tremor in Parkinson disease. Neurology. 2018; 90: e1095–102. DOI: https://doi.org/10.1212/WNL.0000000000005215 

de Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. The Lancet Neurology. 2020; 19: 452–61. DOI: https://doi.org/10.1016/S1474-4422(20)30036-3 

Balestrino R, Schapira AHV. Parkinson disease. European Journal of Neurology. 2020; 27: 27–42. DOI: https://doi.org/10.1111/ene.14108 

Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA – Journal of the American Medical Association. 2014; 311: 1670–83. DOI: https://doi.org/10.1001/jama.2014.3654 

Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice Guideline summary. Neurology. 2021; 97: 942–57. DOI: https://doi.org/10.1212/WNL.0000000000012868 

Fox SH, Lang AE. Levodopa-related motor complications—phenomenology. Mov Disord. 2008; 23(Suppl 3): S509–S514. DOI: https://doi.org/10.1002/mds.22021 

Nonnekes J, Timmer MHM, de Vries NM, et al. Unmasking levodopa resistance in Parkinson’s disease. Movement Disorders. 2016; 31: 1602–9. DOI: https://doi.org/10.1002/mds.26712 

Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain. 1992; 115(Pt 6): 1701–1725. DOI: https://doi.org/10.1093/brain/115.6.1701 

Lee JE, Sweet RD, McDowell FH. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med. 1971; 75(5): 703–708. DOI: https://doi.org/10.7326/0003-4819-75-5-703 

Heusinkveld LE, Hacker ML, Turchan M, et al. Impact of tremor on patients with early stage parkinson’s disease. Frontiers in Neurology. 2018; 9. DOI: https://doi.org/10.3389/fneur.2018.00628 

Zach H, Dirkx M, Pasman JW, et al. The patient’s perspective: The effect of levodopa on Parkinson symptoms. Parkinsonism and Related Disorders. 2017; 35: 48–54. DOI: https://doi.org/10.1016/j.parkreldis.2016.11.015 

Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol. 1986; 43(2): 126–127. DOI: https://doi.org/10.1001/archneur.1986.00520020020009 

Imbach LL, Sommerauer M, Leuenberger K, et al. Dopamine-responsive pattern in tremor patients. Parkinsonism Relat Disord. 2014; 20(11): 1283–1286. DOI: https://doi.org/10.1016/j.parkreldis.2014.09.007 

Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020; 95(11): e1461–e1470. DOI: https://doi.org/10.1212/WNL.0000000000010316 

Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson’s disease. NPJ Parkinsons Dis. 2022; 8(1): 56. Published 2022 May 11. DOI: https://doi.org/10.1038/s41531-022-00321-y 

Gupta HV, Lyons KE, Wachter N, et al. Long Term Response to Levodopa in Parkinson’s Disease. J Parkinsons Dis. 2019; 9(3): 525–529. DOI: https://doi.org/10.3233/JPD-191633 

Caligiuri MP, Lohr JB. Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis. Clin Neuropharmacol. 1993; 16(3): 244–250. DOI: https://doi.org/10.1097/00002826-199306000-00008 

Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002; 72(6): 713–720. DOI: https://doi.org/10.1136/jnnp.72.6.713 

Elble RJ. Tremor and dopamine agonists. Neurology. 2002; 58(4 Suppl 1): S57–S62. DOI: https://doi.org/10.1212/WNL.58.suppl_1.S57 

Frei K, Truong DD. Medications used to treat tremors. J Neurol Sci. 2022; 435: 120194. DOI: https://doi.org/10.1016/j.jns.2022.120194 

Navan P, Findley LJ, Jeffs JA, et al. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s disease. Mov Disord. 2003; 18(2): 176–180. DOI: https://doi.org/10.1002/mds.10320 

Nigro S, Bordier C, Cerasa A, et al. Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson’s disease. Parkinsonism Relat Disord. 2019; 67: 14–20. DOI: https://doi.org/10.1016/j.parkreldis.2019.09.006 

Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother. 1995; 49(4): 197–209. DOI: https://doi.org/10.1016/0753-3322(96)82620-5 

Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019; 33: 905–18. DOI: https://doi.org/10.1007/s40263-019-00661-z 

Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 1990; 53: 1004–7. DOI: https://doi.org/10.1136/jnnp.53.11.1004 

Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018; 91: e189–201. DOI: https://doi.org/10.1212/WNL.0000000000005816 

Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [published correction appears in Arch Neurol.2005 Mar; 62(3): 430]. Arch Neurol. 2004; 61(7): 1044–1053. DOI: https://doi.org/10.1001/archneur.61.7.1044 

Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000; 342(20): 1484–1491. DOI: https://doi.org/10.1056/NEJM200005183422004 

Marras C, Chaudhuri KR, Titova N, et al. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics, 2020; 17: 1366–77. DOI: https://doi.org/10.1007/s13311-020-00894-7 

Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database of Systematic Reviews. 2002; 2010. DOI: https://doi.org/10.1002/14651858.CD003735 

Saeedi Y, Ghadimi M, Rohani M, et al. Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinson’s disease. Clinical Neurology and Neurosurgery. 2021; 202: 106480. DOI: https://doi.org/10.1016/j.clineuro.2021.106480 

van Hilten JJ, Ramaker CC, Stowe R, et al. Bromocriptine versus levodopa in early Parkinson’s disease. Cochrane Database Syst Rev. 2007; 2007(4): CD002258. Published 2007 Oct 17. DOI: https://doi.org/10.1002/14651858.CD002258.pub2 

Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson’s disease. Frontiers in Aging Neuroscience. 2014; 6: 1–9. DOI: https://doi.org/10.3389/fnagi.2014.00180 

Lew MF. Rasagiline treatment effects on parkinsonian tremor. International Journal of Neuroscience. 2013; 123: 859–65. DOI: https://doi.org/10.3109/00207454.2013.812085 

Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol. 2011; 18(12): 1373–1378. DOI: https://doi.org/10.1111/j.1468-1331.2011.03512.x 

Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999; 340(10): 757–763. DOI: https://doi.org/10.1056/NEJM199903113401003 

Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Movement Disorders Clinical Practice. 2016; 3: 116–24. DOI: https://doi.org/10.1002/mdc3.12266 

Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: A retrospective analysis of a large multicentered clinical experience. Movement Disorders. 1998; 13: 377–82. DOI: https://doi.org/10.1002/mds.870130302 

Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010; 33(1): 14–16. DOI: https://doi.org/10.1097/WNF.0b013e3181c47168 

Crosby NJ, Deane K, Clarke CE. Beta-blocker therapy for tremor in Parkinson’s disease. Cochrane Database of Systematic Reviews. 2003; 2010. DOI: https://doi.org/10.1002/14651858.CD003361 

Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013; 73: 1405–15. DOI: https://doi.org/10.1007/s40265-013-0105-4 

Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging. 2000; 16(4): 273–278. DOI: https://doi.org/10.2165/00002512-200016040-00003 

Bullock A, Kaul I, Li S, et al. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. Journal of the Neurological Sciences. 2021; 421: 117277. DOI: https://doi.org/10.1016/j.jns.2020.117277 

Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacological Reviews. 2017; 69: 200–35. DOI: https://doi.org/10.1124/pr.116.012658 

Kreisler A, Bouchain B, Defebvre L, et al. Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor. Tremor Other Hyperkinet Mov (NY). 2019; 9: 10.7916/tohm.v0.640. Published 2019 Jul 26. DOI: https://doi.org/10.5334/tohm.458 

Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021; 13. DOI: https://doi.org/10.3390/toxins13010042 

Niemann N, Jankovic J. Botulinum toxin for the treatment of hand tremor. Toxins (Basel). 2018; 10: 1–10. DOI: https://doi.org/10.3390/toxins10070299 

Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord. 1994; 9(6): 601–609. DOI: https://doi.org/10.1002/mds.870090604 

Mittal SO, Pandey S. Botulinum toxin for the treatment of tremor. Journal of the Neurological Sciences. 2022; 435: 120203. DOI: https://doi.org/10.1016/j.jns.2022.120203 

Mittal SO, Jog M, Lee J, et al. Novel botulinum toxin injection protocols for parkinson tremor and essential tremor – the yale technique and sensor-based kinematics procedure for safe and effective treatment. Tremor and Other Hyperkinetic Movements. 2020; 10: 1–8. DOI: https://doi.org/10.5334/tohm.582 

Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56: 1523–8. DOI: https://doi.org/10.1212/WNL.56.11.1523 

Mittal SO, Machado D, Richardson D, et al. Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. Mayo Clinic Proceedings. 2017; 92: 1359–67. DOI: https://doi.org/10.1016/j.mayocp.2017.06.010 

Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS ONE. 2017; 12: 1–19. DOI: https://doi.org/10.1371/journal.pone.0178670 

Okun MS. Deep-brain stimulation – Entering the era of human neural-network modulation. New England Journal of Medicine. 2014; 371: 1369–73. DOI: https://doi.org/10.1056/NEJMp1408779 

Voges J, Waerzeggers Y, Maarouf M, et al. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery—experiences from a single centre. J Neurol Neurosurg Psychiatry. 2006; 77(7): 868–872. DOI: https://doi.org/10.1136/jnnp.2005.081232 

Hilker R, Benecke R, Deuschl G, et al. Tiefe Hirnstimulation bei idiopathischem Parkinson-Syndrom. Empfehlungen der Deutschen Arbeitsgemeinschaft Tiefe Hirnstimulation [Deep brain stimulation for Parkinson’s disease. Consensus recommendations of the German Deep Brain Stimulation Association]. Nervenarzt. 2009; 80(6): 646–655. DOI: https://doi.org/10.1007/s00115-009-2695-3 

Larson PS. Deep brain stimulation for movement disorders. Neurotherapeutics. 2014; 11(3): 465–474. DOI: https://doi.org/10.1007/s13311-014-0274-1 

Uc EY, Follett KA. Deep brain stimulation in movement disorders. Semin Neurol. 2007; 27(2): 170–182. DOI: https://doi.org/10.1055/s-2007-971175 

Siddiqui MS, Haq IU, Okun MS. Deep brain stimulation in movement disorders. Continuum (Minneap Minn). 2010; 16(1 Movement Disorders): 110–130. DOI: https://doi.org/10.1212/01.CON.0000348903.94715.b4 

Defer GL, Widner H, Marié RM, et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson’s disease (CAPSIT-PD). Movement Disorders. 1999; 14: 572–84. DOI: https://doi.org/10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C 

Munhoz RP, Picillo M, Fox SH, et al. Eligibility Criteria for Deep Brain Stimulation in Parkinson’s Disease, Tremor, and Dystonia. Can J Neurol Sci. 2016; 43(4): 462–471. DOI: https://doi.org/10.1017/cjn.2016.35 

Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. Journal of Neurology. 2021; 268: 3135–43. DOI: https://doi.org/10.1007/s00415-020-09810-7 

Hirsch EC, Mouatt A, Faucheux B, et al. Dopamine, tremor, and Parkinson’s disease. Lancet. 1992; 340(8811): 125–126. DOI: https://doi.org/10.1016/0140-6736(92)90457-E 

Zheng Z, Yin Z, Zhang B, et al. Levodopa Challenge Test Predicts STN-DBS Outcomes in Various Parkinson’s Disease Motor Subtypes: A More Accurate Judgment. Neural Plasticity; 2021. DOI: https://doi.org/10.1155/2021/4762027 

Lin W, Shi D, Wang D, et al. Can Levodopa Challenge Testing Predict the Effect of Deep Brain Stimulation? One-Year Outcomes in a Chinese Cohort. Frontiers in Aging Neuroscience. 2021; 13: 1–7. DOI: https://doi.org/10.3389/fnagi.2021.764308 

Sandoe C, Krishna V, Basha D, et al. Predictors of deep brain stimulation outcome in tremor patients. Brain Stimulation. 2018; 11: 592–9. DOI: https://doi.org/10.1016/j.brs.2017.12.014 

Karas PJ, Mikell CB, Christian E, et al. Deep brain stimulation: a mechanistic and clinical update. Neurosurg Focus. 2013; 35(5): E1. DOI: https://doi.org/10.3171/2013.9.FOCUS13383 

Hwang JH, Paek SH, Jeon BS. Deep brain stimulation: mechanism, surgical procedure, and clinical applications. J Korean Med Assoc. 2013; 56(8): 695–701. DOI: https://doi.org/10.5124/jkma.2013.56.8.695 

Ashkan K, Rogers P, Bergman H, et al. Insights into the mechanisms of deep brain stimulation. Nat Rev Neurol. 2017; 13(9): 548–554. DOI: https://doi.org/10.1038/nrneurol.2017.105 

Herrington TM, Cheng JJ, Eskandar EN. Mechanisms of deep brain stimulation. Journal of Neurophysiology. 2016; 115: 19–38. DOI: https://doi.org/10.1152/jn.00281.2015 

Chiken S, Nambu A. Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption? Neuroscientist. 2016; 22: 313–22. DOI: https://doi.org/10.1177/1073858415581986 

Mure H, Hirano S, Tang CC, et al. Parkinson’s disease tremor-related metabolic network: Characterization, progression, and treatment effects. Neuroimage. 2011; 54: 1244–53. DOI: https://doi.org/10.1016/j.neuroimage.2010.09.028 

Peng S, Dhawan V, Eidelberg D, et al. Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders. Bioelectronic Medicine. 2021; 7. DOI: https://doi.org/10.1186/s42234-021-00065-9 

Little S, Beudel M, Zrinzo L, et al. Bilateral adaptive deep brain stimulation is effective in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2016; 87: 717–21. DOI: https://doi.org/10.1136/jnnp-2015-310972 

Alberts JL, Hass CJ, Vitek JL, et al. Are two leads always better than one: An emerging case for unilateral subthalamic deep brain stimulation in Parkinson’s disease. Experimental Neurology. 2008; 214: 1–5. DOI: https://doi.org/10.1016/j.expneurol.2008.07.019 

Mao Z, Ling Z, Pan L, et al. Comparison of efficacy of deep brain stimulation of different targets in Parkinson’s disease: A network meta-analysis. Frontiers in Aging Neuroscience. 2019; 10: 1–8. DOI: https://doi.org/10.3389/fnagi.2019.00023 

Groiss SJ, Wojtecki L, Sudmeyer M, et al. Deep brain stimulation in Parkinson-s disease. Therapeutic Advances in Neurological Disorders. 2009; 2: 379–91. DOI: https://doi.org/10.1177/1756285609339382 

Honey CR, Hamani C, Kalia SK, et al. Deep Brain Stimulation Target Selection for Parkinson’s Disease. Canadian Journal of Neurological Sciences. 2017; 44: 3–8. DOI: https://doi.org/10.1017/cjn.2016.22 

Wong JK, Viswanathan VT, Nozile-Firth KS, et al. STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson’s Disease. Front Hum Neurosci. 2020; 14: 578615. Published 2020 Oct 23. DOI: https://doi.org/10.3389/fnhum.2020.578615 

Katlowitz K, Ko M, Mogilner AY, et al. Effect of deep brain simulation on arm, leg, and chin tremor in Parkinson disease [published online ahead of print, 2018 Dec 7]. J Neurosurg. 2018; 1–6. DOI: https://doi.org/10.3171/2018.7.JNS18784 

Lin Z, Zhang X, Wang L, et al. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson’s Disease. Frontiers in Human Neuroscience. 2021; 15: 1–10. DOI: https://doi.org/10.3389/fnhum.2021.604433 

Lyons KE, Koller WC, Wilkinson SB, et al. Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor. Journal of Neurology Neurosurgery and Psychiatry. 2001; 71: 682–4. DOI: https://doi.org/10.1136/jnnp.71.5.682 

Hartmann CJ, Fliegen S, Groiss SJ, et al. An update on best practice of deep brain stimulation in Parkinson’s disease. Therapeutic Advances in Neurological Disorders. 2019; 12: 1–20. DOI: https://doi.org/10.1177/1756286419838096 

Azghadi A, Rajagopal MM, Atkinson KA, et al. Tremor on medication. 2022; 136: 1364–70. DOI: https://doi.org/10.3171/2021.4.JNS21502 

Hitti FL, Ramayya AG, McShane BJ, et al. Long-term outcomes following deep brain stimulation for Parkinson’s disease [published online ahead of print, 2019 Jan 18]. J Neurosurg. 2019; 1–6. DOI: https://doi.org/10.3171/2018.8.JNS182081 

Fukaya C, Watanabe M, Kobayashi K, et al. Predictive factors for long-term outcome of subthalamic nucleus deep brain stimulation for parkinson’s disease. Neurologia Medico-Chirurgica. 2017; 57: 166–71. DOI: https://doi.org/10.2176/nmc.oa.2016-0114 

Bove F, Mulas D, Cavallieri F, et al. Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease. Neurology. 2021; 97: E254–62. DOI: https://doi.org/10.1212/WNL.0000000000012246 

Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019; 15: 234–42. DOI: https://doi.org/10.1038/s41582-019-0145-9 

Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Movement Disorders. 2010; 25: 578–86. DOI: https://doi.org/10.1002/mds.22735 

Volkmann J, Albanese A, Kulisevsky J, et al. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson’s disease. Movement Disorders. 2009; 24: 1154–61. DOI: https://doi.org/10.1002/mds.22496 

Hariz MI, Krack P, Alesch F, et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: A 6 year follow-up. Journal of Neurology, Neurosurgery and Psychiatry. 2008; 79: 694–9. DOI: https://doi.org/10.1136/jnnp.2007.118653